Multiple Myeloma

Most recent

Dr. Richard LeBlanc: Impressive Results from POLLUX Trial

The addition of daratumumab to lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) alone was evaluated in the POLLUX trial, a randomized, open-label, multicentre, phase III study. The population of the study included 569 patients with multiple...

Other

Twitter feed

Dr. Irwindeep Sandhu provides an analysis of the TOURMALINE-MM3 study with post-ASCT patients receiving #ixazomib m… https://t.co/ll9s4q7vCL
h J R
Dr. Brian Leber discusses long-term follow-up of patients with #myelofibrosis treated with #JAK inhibitors #EHA2019… https://t.co/G4FuspL3NK
h J R
Dr. Darrell White writes about the impact of age on efficacy and safety from the MAIA trial in transplant-ineligibl… https://t.co/00XDPvNCVo
h J R
Dr. Irwindeep Sandhu talks about the importance of studying real-world Canadian data in #multiplemyeloma #EHA2019… https://t.co/WHNsd75EPZ
h J R
Dr. Brian Leber discusses a re-analysis of the JAKARTA-2 study in patients with myeloproliferative neoplasm-associa… https://t.co/GyZFmwk7sq
h J R